VC  SV Health Investors

     Office Locations:

One Boston Place
201 Washington Street, Suite 3900
Boston, MA 02108
Phone: 617-367-8100
Fax: 617-367-1590

Get all office locations for this firm with a National Database subscription.


  • Early
  • Expansion
  • Growth
  • Seed



  • Life Sciences & Healthcare
  • Medical Device



    SV Health Investors (formerly SV Life Sciences) is a leading international life sciences venture capital firm. SV affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SV team manages five private venture capital funds with approximately $2.0 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVL has offices in Boston and London. SV was started in London as Schroder Ventures Life Sciences in 1993 as part of the Schroder Ventures Group. SVLS became independent of the Schroder Ventures Group in 2001, and in January 2005 changed its name to SV Life Sciences to reflect independent ownership. The firm usually commits $1 to $40 million per company, diversifying its portfolio by sub sector, geography and stage of company. SVLSFV has total commitments of $3b (plus $11 million of co-investments committed by partners and individuals affiliated with SVLS). As of September 2011 the Fund had invested $78m in 19 portfolio companies.



      Fund Name



    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Eugene Hill Chairman
    Kate Bingham Managing Partner
    Michael Balmuth Managing Partner
    Michael Ross Ph.D. Managing Partner
    Niyoshi Patel Associate


    Recent Funding Events (trailing 12 months):












      Nimbus Therapeutics





      Rondo Therapeutics



      Series A


    Portfolio companies include:


    Recent News: